

I CLAIM:

1. Pharmaceutical composition comprising:

an hypcholesterolemic agent, said  
hypcholesterolemic agent being preferably selected  
from the group consisting of benfluorex and  
ursodesoxycolic acid;

an hypotriglyceride agent, said hypotriglyceride  
agent being preferably benfluorex;

a lipasic and proteasic agent, said lipasic and  
proteasic agent being preferably pancreatine IX F.U.;

an hypoglycemic agent, said hypoglycemic agent  
being preferably metformine and

an hydrocoleretic agent, said hydrocoleretic agent  
being preferably selected from the group consisting of  
Na dehydrocloate and ursodesoxycolic acid.

2. Pharmaceutical composition according to claim 1,  
wherein:

said benfluorex is present in a global amount from  
7% to 23% in weight of the total amount of the  
composition;

said pancreatine IX F.U. is present in an amount  
from 27% to 43% in weight of the total amount of the  
composition;

said metformine is present in an amount from 36%  
to 41% in weight of the total amount of the

composition;

said Na dehydrocloate is present in an amount from 9% to 14% of the total amount of the composition.

3. Pharmaceutical composition according to claim 1, wherein:

said benfluorex is present in a global amount from 7% to 18% in weight of the total amount of the composition;

said pancreatine IX F.U. is present in an amount from 22% to 43% in weight of the total amount of the composition;

said metformine is present in an amount from 33% to 36% in weight of the total amount of the composition;

said ursodesoxycolic acid is present in an amount from 14% to 17% of the total amount of the composition.

4. Pharmaceutical composition according to claim 1, wherein the composition further comprises:

- an hypouricemic agent, said hypouricemia agent being preferably centella asiatica purified triterpenes; and/or

- a radical scavenger agent, said radical scavenger agent being preferably selenium; and/or

- a sympatholytic agent, said sympatholytic agent

being preferably yohimbine; and/or

- a sympathicomimetic agent, said sympathicomimetic agent being selected from the group consisting of phendimetrazinum bitartrate and phendimetrazinum pamoate; and/or

- at least one vitamin, said at least one vitamin being selected from the group consisting of vitamin A, vitamin B<sub>1</sub>, vitamin B<sub>6</sub>, vitamin E and vitamin C.

5. Pharmaceutical composition according to claim 1, wherein the composition further comprises at least one diet adjuvant selected from the group consisting of sedative-ansiolytic agents, anorectic agents and lipolytic agents.

6. Pharmaceutical composition according to claim 4, wherein the composition further comprises at least one diet adjuvant selected from the group consisting of sedative-ansiolytic agents, anorectic agents and lipolytic agents.

7. Pharmacological composition according to claim 2, comprising:

- centella asiatica purified triterpenes in a ratio from 0,04:1 to 0,5:1 in weight with respect to the total weight of the composition; and/or

- selenium in a ration from 0,09:1 to 0,3:1 in weight with respect to the total weight of the composition;

and/or

- yohimbine in a ratio from 0,0009:1 to 0,007:1 in weight with respect to the total weight of the composition; and/or

- phendimetrazine bitartarate or phendimetrazine pamoate in a ratio from 0,004:1 to 0,13:1 in weight with respect to the total weight of the composition; and/or

- vitamin A in a ratio from 0,5:1 to 1,8:1 in weight with respect to the total weight of the composition; and/or

- vitamin B<sub>1</sub> in a ratio from 0,002:1 to 0,007:1 in weight with respect to total weight of the composition; and/or

- vitamin B<sub>6</sub> in a ratio from 0,05:1 to 0,2:1 in weight with respect to the total weight of the composition; and/or

- vitamin E in a ratio from 0,09:1 to 1:1 in weight with respect to the total weight of the composition; and/or

- vitamin C in a ratio from 0,09:1 to 0,3:1 in weight with respect to the total weight of the composition.

8. Pharmacological composition according to claim 3, comprising:

- centella asiatica purified triterpenes in a ratio from 0,04:1 to 0,5:1 in weight with respect to the total

weight of the composition; and/or

- selenium in a ration from 0,09:1 to 0,3:1 in weight with respect to the total weight of the composition; and/or

- yohimbine in a ratio from 0,0009:1 to 0,007:1 in weight with respect to the total weight of the composition; and/or

- phendimetrazine bitartarate or phendimetrazine pamoate in a ratio from 0,004:1 to 0,13:1 in weight with respect to the total weight of the composition; and/or

- vitamin A in a ratio from 0,5:1 to 1,8:1 in weight with respect to the total weight of the composition; and/or

- vitamin B<sub>1</sub> in a ratio from 0,002:1 to 0,007:1 in weight with respect to total weight of the composition; and/or

- vitamin B<sub>6</sub> in a ratio from 0,05:1 to 0,2:1 in weight with respect to the total weight of the composition; and/or

- vitamin E in a ratio from 0,09:1 to 1:1 in weight with respect to the total weight of the composition; and/or

- vitamin C in a ratio from 0,09:1 to 0,3:1 in weight with respect to the total weight of the composition.

9. Pharmaceutical composition according to claim 2,

comprising:

- a sedative-ansiolityc agent being preferably a benzodiazepine, most preferably dipotassium chlorazepate in a ratio from 0,0005:1 to 0,03:1 in weight with respect to the total weight of the composition; and/or
- an anorectic agent selected from the group consisting of diethylpropione chlorhydrate, fenfluramine chlohydrate, D- fenfluramine chlohydrate, said anorectic agent being present in a ratio from 0,002:1 to 1,3:1 in weight with respect to the total weight of the composition; and/or
- a lipilityc agent selected from the group consisting of analogues of tiroxine, preferably being triiodictiroacetic acid which is present in a ratio from 0,0002:1 to 0,003:1 in weight with respect to the total weight of the composition.

10. Pharmaceutical composition according to claim 3,  
comprising:

- a sedative-ansiolityc agent being preferably a benzodiazepine, most preferably dipotassium chlorazepate in a ratio from 0,0005:1 to 0,03:1 in weight with respect to the total weight of the composition; and/or
- an anorectic agent selected from the group consisting of diethylpropione chlorhydrate, fenfluramine chlohydrate, D- fenfluramine chlohydrate, said anorectic

agent being present in a ratio from 0,002:1 to 1,3:1 in weight with respect to the total weight of the composition; and/or

- a lipilityc agent selected from the group consisting of analogues of tiroxine, preferably being triiodotiroacetic acid which is present in a ratio from 0,0002:1 to 0,003:1 in weight with respect to the total weight of the composition.

11. Pharmaceutical composition according to claim 1, which further comprises suitable pharmaceutically acceptable excipients.

12. Pharmaceutical composition according to claim 5, which further comprises suitable pharmaceutically acceptable excipients.

13. Pharmaceutical composition according to claim 6, which further comprises suitable pharmaceutically acceptable excipients.

14. Pharmaceutical composition according claim 11, wherein said composition is a solid composition for oral administration comprising compressed tablets, dispersible powders, granules and gelatine capsules.

15. Pharmaceutical composition according claim 12, wherein said composition is a solid composition for oral administration comprising compressed tablets, dispersible powders, granules and gelatine capsules.

16. Pharmaceutical composition according claim 13, wherein said composition is a solid composition for oral administration comprising compressed tablets, dispersible powders, granules and gelatine capsules.

17. Kit of parts for the simultaneous, sequential or separated administration, comprising:

an hypocholesterolemic agent, said hypocholesterolemic agent being preferably selected from the group consisting of benfluorex and ursodesoxycolic;

an hypotriglyceride agent, said hypotriglyceride agent being preferably benfluorex;

a lipasic and proteasic agent, said lipasic and proteasic agent being preferably pancreatine IX F.U.;

an hypoglycemic agent, said hypoglycemic agent being preferably metformine and

an hydrocoleretic agent, said hydrocoleretic agent being preferably selected from the group consisting of Na dehydrocloate and ursodesoxycolic acid.

18. Kit according to claim 17, which further comprises:

- an hypouricemic agent, said hypouricemic agent being preferably centella asiatica purified triterpenes; and/or

- a radical scavenger agent, said radical scavenger

DOCUMENT NUMBER

agent being preferably selenium; and/or

- a sympatholytic agent, said sympatholytic agent being preferably yohimbine; and/or

- a sympathicomimetic agent, said sympathicomimetic agent being selected from the group consisting of phendimetrazinum bitartarate and phendimetrazinum pamoate; and/or

- at least one vitamin, said at least one vitamin being selected from the group consisting of vitamin A, vitamin B<sub>1</sub>, vitamin B<sub>6</sub>, vitamin E and vitamin C; and/or

- at least one adjuvant selected from the group consisting of a sedative-ansiolytic agent, an anorectic agent and a lipolytic agent.

19. Kit according to claim 18, wherein:

- said sedative-ansiolitic agent is preferably a benzodiazepine, most preferably dipotassium chlorazepate;

- said anorectic agent is preferably selected from the group consisting of diethylpropione chlorhydrate, fenfluramine chlohydrate, D- fenfluramine chlohydrate;

- said lipolytic agent is preferably selected from the group consisting of analogues of tiroxine, most preferably being triiodiotiroacetic acid.

20. Method for preventing or treating side-effects of ketogenic diet, which comprises the administration of the composition of claim 1.

21. Method for preventing or treating side-effects of ketogenic diet, which comprises the administration of the composition of claim 4.

22. Method for preventing or treating side-effects of ketogenic diet, which comprises the administration of the composition of claim 5.

23. Method according to claim 20, wherein said composition is orally administered in doses from 7g to 23g a day to a patient of the weight of about 70kg.

24. Method according to claim 21, wherein said composition is orally administered in doses from 7g to 23g a day to a patient of the weight of about 70kg.

25. Method according to claim 22, wherein said composition is orally administered in doses from 7g to 23g a day to a patient of the weight of about 70kg.

*add  
at*

*add  
13-1*